Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.
尽管周五美国股市收盘大多走低，但仍有一些值得注意的内幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
当内部人士购买股票时，这表明他们对公司前景充满信心，或者他们认为股票很划算。无论哪种方式，这都预示着做多该股的机会。不应将内幕购买视为做出投资或交易决策的唯一指标。充其量，它可以为购买决定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的内幕收购。欲了解更多，请查看 本辛加的内幕交易 平台。
Harrow
耙
- The Trade: Harrow, Inc. (NASDAQ:HROW) 10% owner Opaleye Management Inc. acquired a total of 50,600 shares an average price of $9.65. To acquire these shares, it cost around $488,290.
- What's Happening: On March 19, Harrow reported worse-than-expected fourth-quarter financial results.
- What Harrow Does: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.
- 交易：哈罗公司（纳斯达克股票代码：HROW）10％的所有者Opaleye Management Inc. 共收购了50,600股股票 平均价格为9.65美元。收购这些股票的成本约为488,290美元。
- 发生了什么：3月19日，哈罗公布的第四季度财务业绩低于预期。
- 哈罗做什么：哈罗公司是一家眼部护理制药公司，致力于为美国市场发现、开发和商业化眼科药品。
Greenwich LifeSciences
格林威治生命科学
- The Trade: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO and CFO Snehal Patel acquired a total of 1,500 shares at an average price of $17.68. To acquire these shares, it cost around $26,520.
- What's Happening: On March 12, Greenwich LifeSciences announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.
- What Greenwich LifeSciences Does: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
- 交易：格林威治生命科学公司（纳斯达克股票代码：GLSI）首席执行官兼首席财务官斯内哈尔·帕特尔共收购了1,500股股票，平均价格为17.68美元。收购这些股票的成本约为26,520美元。
- 发生了什么：3月12日，格林威治生命科学宣布与西班牙GEICAM合作启动欧洲首批临床研究所。
- 格林威治生命科学公司做什么：格林威治生命科学公司是一家临床阶段的生物制药公司，专注于开发GP2，这是一种免疫疗法，旨在防止先前接受过手术的患者乳腺癌复发。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
BRT Apartments
BRT 公寓
- The Trade: BRT Apartments Corp. (NYSE:BRT) 10% owner Gould Investors L P bought a total of 3,471shares at an average price of $16.26. To acquire these shares, it cost around $56,450.
- What's Happening: On March 12, BRT Apartments posted downbeat quarterly sales.
- What BRT Apartments Does: BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties.
- 交易：BRT Apartments Corp.（纽约证券交易所代码：BRT）10% 的所有者 Gould Investors L P 共购买了3,471股股票 平均价格为16.26美元。收购这些股票的成本约为56,450美元。
- 发生了什么：3月12日，BRT公寓公布了悲观的季度销售额。
- BRT公寓做什么：BRT公寓公司是一家房地产投资信托公司。该公司主要专注于多户住宅物业的所有权、运营和开发。
译文内容由第三方软件翻译。